Deliver Your News to the World

Patent Issued to Inhalation, Inc. on Methods to Prevent, Treat, and Cure Infections of Severe Acute Respiratory Syndrome (SARS), Tuberculosis, and Other Respiratory Infections


Woodinville, Wash., May 23, 2006 - Inhalation, Inc. was issued the U.S. Patent today entitled “Methods and Apparatus to Prevent, Treat, and Cure Infections of the Human Respiratory System by Pathogens Causing Severe Acute Respiratory Syndrome (SARS)” which is U.S. Patent No. 7,048,953.

The patent describes methods of inhaling the vapors from 100% botanical essential oils to prevent, treat and cure infections of SARS. These botanical essential oils include Eucalyptus oil (Eucalyptus globulus) and Tea Tree oil (Melaleuca alternifolia). The patent describes these oils as possessing significant antibacterial, antiviral, and antifungal properties that are useful as broad-spectrum antiseptics and which volatile vapors may be safely inhaled.

The patent also describes inhaling such vapors to prevent, treat, and cure infections of Mycobacterium tuberculosis that causes TB. In addition, the patent describes inhaling such vapors to prevent, treat, and cure various respiratory influenza infections. W. Banning Vail, Ph.D., a MIT-trained physicist and holder of over 65 patents worldwide, and Marilyn L. Vail, president of Inhalation, Inc., are the co-inventors of the patent.

Other research confirms that vapors from plant-based essential oils can eradicate a wide variety of pathogens. Japanese researchers, Shigeharu Inouye, Toshio Takizawa and Hideyo Yamaguchi published their paper entitled “Antibacterial activity of essential oils and their major constituents against respiratory tract pathogens by gaseous contact” in the Journal of Antimicrobial Chemotherapy, Vol. 47, 2001, pages 565-573. In addition, Shigeharu Inouye also published the paper entitled “Laboratory Evaluation of Gaseous Essential Oils (Part 1)” in The International Journal of Aromatherapy, Volume 13, Issues 2-3, 2003, pages 95-107.

Botanical essential oils are proving to have many other significant medical uses. For example, Eugene Sherry, M.D., and P.H. Warnke, Ph.D., presented “Alternative for MRSA and Tuberculosis (TB): Eucalyptus and Tea-Tree Oils as New Topical Antibacterials” at the American Academy of Orthopaedic Surgeons, February 13-17, 2002. Further, E. Sherry, S. Sivananthan, P.H. Warnke, and G.D. Eslick published the paper entitled “Topical phytochemicals used to salvage the gangrenous lower limbs of type 1 diabetic patients”, in Diabetes Research Clinical Practice, Vol. 62, 2003, pages 65-66. In addition, E. Sherry, M. Reynolds, S. Sivananthan, S. Mainawalala, and P.H. Warnke also published the paper entitled “Inhalational Phytochemicals as Possible Treatment for Pulmonary Tuberculosis: Two case reports”, American Journal for Infectious Control, Vol. 32, 2004, pages 369-370.

The company was previously granted U.S. Patent No. 6, 447,816 entitled “Methods and Apparatus to Prevent Colds, Flus, and Infections of the Human Respiratory System” that issued on September 10, 2002. Other U.S. patent applications filed by the Vails include the following titles: “Methods and Apparatus to Prevent Colds, Influenzas, Tuberculosis and Opportunistic Infections of the Human Respiratory System” (which will also issue shortly as a patent in the United States Patent and Trademark Office); “Methods and Apparatus to Prevent, Treat, and Cure Infections of the Human Respiratory System from Inhaled Anthrax, Smallpox, Botulism, Plague, Tularemia, Hemorrhagic Fever Viruses, Tuberculosis and Other Inhaled Bioterrorism Pathogens”; and “Methods and Apparatus to Prevent Treat, and Cure the Symptoms of Nausea Caused by Chemotherapy Treatments of Human Cancers (that was Published on July 21, 2005 as US 2005/0158411 A1).

A section of the latter published patent application further describes inhaling such vapors to prevent, treat, and cure infections of avian influenza A (H5N1) that is the so-called “bird flu” or “avian flu”. The approaches in these patent applications claim the inhalation of antiseptic vapors from various essential oils or combination of oils. Inhalation, Inc. is in the process of testing such approaches.

About Inhalation, Inc.

Inhalation, Inc., based in Woodinville, WA, was founded in 2000 to pioneer the use of inhaled vapors from 100% pure botanical essential oils to prevent, treat, and cure a wide range of human respiratory diseases. These inhaled substances have an immediate and direct impact on the entire respiratory system, which is in contrast to ingested medications and typical vaccines. The company provides other inhalers containing essential oils that have been used for years to address headaches, stress, insomnia, nausea, and women’s health issues. More information on the company and its products (including quotes from experts on these subjects) is available at, or by calling (425) 398-2557.


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.